Comparison 17.
Appearance of ascites ‐ absolute risk difference (ARD)
| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
|---|---|---|---|---|
| 1 All studies | 8 | 582 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.14 [‐0.21, ‐0.08] |
| 2 Parenteral nutrition | 4 | 214 | Risk Difference (M‐H, Random, 95% CI) | ‐0.16 [‐0.30, ‐0.03] |
| 2.1 Medical trials | 2 | 26 | Risk Difference (M‐H, Random, 95% CI) | ‐0.13 [‐0.48, 0.22] |
| 2.2 Surgical trials | 2 | 188 | Risk Difference (M‐H, Random, 95% CI) | ‐0.20 [‐0.34, ‐0.07] |
| 3 Enteral nutrition | 0 | 0 | Risk Difference (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] |
| 3.1 Medical trials | 0 | 0 | Risk Difference (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] |
| 3.2 Surgical trials | 0 | 0 | Risk Difference (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] |
| 4 Supplements | 4 | 368 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.11 [‐0.19, ‐0.03] |
| 4.1 Medical trials | 4 | 368 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.11 [‐0.19, ‐0.03] |
| 4.2 Surgical trials | 0 | 0 | Risk Difference (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] |
| 5 Medical trials | 6 | 394 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.11 [‐0.19, ‐0.04] |
| 5.1 Parenteral nutrition | 2 | 26 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.14 [‐0.41, 0.12] |
| 5.2 Enteral nutrition | 0 | 0 | Risk Difference (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] |
| 5.3 Supplements | 4 | 368 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.11 [‐0.19, ‐0.03] |
| 6 Surgical trials | 2 | 188 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.21 [‐0.34, ‐0.07] |
| 6.1 Parenteral nutrition | 2 | 188 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.21 [‐0.34, ‐0.07] |
| 6.2 Enteral nutrition | 0 | 0 | Risk Difference (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] |
| 6.3 Supplements | 0 | 0 | Risk Difference (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] |
| 7 Alcoholic hepatitis | 3 | 77 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.14 [‐0.33, 0.06] |
| 7.1 Parenteral nutrition | 2 | 26 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.14 [‐0.41, 0.12] |
| 7.2 Enteral nutrition | 0 | 0 | Risk Difference (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] |
| 7.3 Supplements | 1 | 51 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.13 [‐0.40, 0.13] |
| 8 Cirrhosis | 2 | 82 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.08 [‐0.26, 0.09] |
| 8.1 Parenteral nutrition | 0 | 0 | Risk Difference (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] |
| 8.2 Enteral nutrition | 0 | 0 | Risk Difference (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] |
| 8.3 Supplements | 2 | 82 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.08 [‐0.26, 0.09] |
| 9 HCC | 2 | 286 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.12 [‐0.21, ‐0.03] |
| 9.1 Parenteral nutrition | 0 | 0 | Risk Difference (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] |
| 9.2 Enteral nutrition | 0 | 0 | Risk Difference (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] |
| 9.3 Supplements | 2 | 286 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.12 [‐0.21, ‐0.03] |
| 10 Abstracts excluded | 7 | 380 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.17 [‐0.25, ‐0.08] |
| 10.1 Parenteral nutrition ‐ medical trials | 2 | 26 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.14 [‐0.41, 0.12] |
| 10.2 Parenteral nutrition ‐ surgical trials | 2 | 188 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.21 [‐0.34, ‐0.07] |
| 10.3 Enteral nutrition ‐ medical trials | 0 | 0 | Risk Difference (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] |
| 10.4 Enteral nutrition = surgical trials | 0 | 0 | Risk Difference (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] |
| 10.5 Supplements ‐ medical trials | 3 | 166 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.12 [‐0.24, ‐0.01] |
| 10.6 Supplements ‐ surgical trials | 0 | 0 | Risk Difference (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] |
| 11 Surgical trials without transplant | 2 | 188 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.21 [‐0.34, ‐0.07] |
| 11.1 Parenteral nutrition | 2 | 188 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.21 [‐0.34, ‐0.07] |
| 11.2 Enteral nutrition | 0 | 0 | Risk Difference (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] |
| 11.3 Supplements | 0 | 0 | Risk Difference (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] |
| 12 Intent to treat ‐ best‐case scenario for intervention | 8 | 626 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.20 [‐0.27, ‐0.14] |
| 12.1 Parenteral nutrition ‐ medical trials | 2 | 26 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.14 [‐0.41, 0.12] |
| 12.2 Parenteral nutrition ‐ surgical trials | 2 | 214 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.31 [‐0.43, ‐0.19] |
| 12.3 Enteral nutrition ‐ medical trials | 0 | 0 | Risk Difference (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] |
| 12.4 Enteral nutrition ‐ surgical trials | 0 | 0 | Risk Difference (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] |
| 12.5 Supplements ‐ medical trials | 4 | 386 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.15 [‐0.23, ‐0.07] |
| 12.6 Supplements ‐ surgical trials | 0 | 0 | Risk Difference (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] |
| 13 Intent to treat ‐ worst‐case scenario for intervention | 8 | 626 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.06 [‐0.13, 0.00] |
| 13.1 Parenteral nutrition ‐ medical trials | 2 | 26 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.14 [‐0.41, 0.12] |
| 13.2 Parenteral nutrition ‐ surgical trials | 2 | 214 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.06 [‐0.19, 0.07] |
| 13.3 Enteral nutrition ‐ medical trials | 0 | 0 | Risk Difference (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] |
| 13.4 Enteral nutrition = surgical trials | 0 | 0 | Risk Difference (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] |
| 13.5 Supplements ‐ medical trials | 4 | 386 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.06 [‐0.14, 0.02] |
| 13.6 Supplements ‐ surgical trials | 0 | 0 | Risk Difference (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] |